BLOXIVERZ Drug Patent Profile

« Back to Dashboard

Which patents cover Bloxiverz, and when can generic versions of Bloxiverz launch?

Bloxiverz is a drug marketed by Exela Pharma and is included in one NDA.

The generic ingredient in BLOXIVERZ is neostigmine methylsulfate. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bloxiverz

A generic version of BLOXIVERZ was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8^th, 2015.

Summary for BLOXIVERZ

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	1
Patent Applications:	1,119
Drug Prices:	Drug price information for BLOXIVERZ
What excipients (inactive ingredients) are in BLOXIVERZ?	BLOXIVERZ excipients list
DailyMed Link:	BLOXIVERZ at DailyMed

See drug prices for BLOXIVERZ

Recent Clinical Trials for BLOXIVERZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	Phase 4
Merck Sharp & Dohme LLC	Phase 4

See all BLOXIVERZ clinical trials

Pharmacology for BLOXIVERZ

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

US Patents and Regulatory Information for BLOXIVERZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exela Pharma	BLOXIVERZ	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	204078-001	May 31, 2013		DISCN	Yes	No
Exela Pharma	BLOXIVERZ	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	204078-003	Oct 27, 2023		DISCN	Yes	No
Exela Pharma	BLOXIVERZ	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	204078-002	May 31, 2013		DISCN	Yes	No

BLOXIVERZ Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: October 30, 2026

BLOXIVERZ is a niche hospital injectable containing neostigmine methylsulfate for reversal of nondepolarizing neuromuscular blockade after surgery. Its commercial profile is shaped by low unit volume, recurring operating-room demand, hospital purchasing contracts, generic injectable competition, and substitution from sugammadex. The product’s revenue has historically been meaningful for a small specialty portfolio but is not separately disclosed in recent public financial reporting.

The principal commercial risk is generic erosion rather than loss of clinical demand. The principal competitive risk is sugammadex, which offers selective reversal of rocuronium- and vecuronium-induced blockade and has expanded in anesthesia practice. BLOXIVERZ retains demand where hospitals manage cost, use neostigmine for appropriate levels of blockade, or face formulary restrictions on sugammadex.

What is BLOXIVERZ and how is it used?

BLOXIVERZ is an injectable formulation of neostigmine methylsulfate, an acetylcholinesterase inhibitor. It is administered intravenously to reverse the effects of nondepolarizing neuromuscular blocking agents after surgery.

The FDA-approved product is used with an anticholinergic agent, such as glycopyrrolate or atropine, to reduce clinically significant bradycardia and other cholinergic effects. The label provides weight-based dosing, generally up to a maximum of 5 mg, based on the degree of neuromuscular recovery and clinical monitoring.[1]

Attribute	BLOXIVERZ profile
Active ingredient	Neostigmine methylsulfate
Dosage form	Intravenous injection
Primary setting	Operating rooms and post-anesthesia care
Main use	Reversal of nondepolarizing neuromuscular blockade
FDA pathway	505(b)(2) application
Initial FDA approval	2013
Principal buyers	Hospitals, health systems, group purchasing organizations
Key alternatives	Generic neostigmine and sugammadex
Commercial category	Branded hospital injectable

Neostigmine is an established active ingredient. BLOXIVERZ’s value came from FDA approval of a standardized injectable product, clinical labeling, manufacturing controls, and commercial availability rather than from a newly discovered pharmacologic mechanism.

What is the FDA regulatory status of BLOXIVERZ?

The FDA approved BLOXIVERZ in 2013 through the 505(b)(2) pathway. That pathway allows an applicant to rely partly on previously established safety or efficacy information while supporting differences in formulation, dosage form, labeling, or other product characteristics.[2]

Because neostigmine was an established drug, BLOXIVERZ did not receive the five-year new chemical entity exclusivity available to a novel active ingredient. The product received the type of three-year exclusivity generally associated with approval of new clinical investigations or other changes that are essential to approval under Section 505(b)(2). That period has expired.

FDA exclusivity timeline

Milestone	Timing	Commercial impact
FDA approval	2013	Established U.S. branded product
Three-year regulatory exclusivity	Approximately 2013-2016	Delayed reliance-based approvals tied to protected approval elements
Post-exclusivity period	From approximately 2016	Enabled competitive development and potential ANDA or 505(b)(2) entry
Current status	Mature product	Revenue depends on supply, contracts, labeling, and patent barriers

BLOXIVERZ is not a biologic, so biosimilar regulation does not apply. Competitive products would be approved as generic drugs or under the 505(b)(2) pathway, depending on formulation and reliance strategy.

What patents protect BLOXIVERZ?

The relevant patent estate is narrower than the estate for a newly discovered drug. Public Orange Book records have associated BLOXIVERZ with U.S. Patent No. 8,563,033, covering aspects of neostigmine compositions and use.[3]

The patent is important because it can delay approval or commercial launch of a competing product even after regulatory exclusivity expires. Its practical value depends on claim scope, Orange Book listing status, patent-term calculations, and the outcome of any Paragraph IV litigation.

Patent issue	BLOXIVERZ assessment
Core active ingredient patent	None of commercial significance; neostigmine is an old active ingredient
Product/formulation protection	Historically linked to U.S. Patent No. 8,563,033
Regulatory exclusivity	Expired
Orange Book relevance	Patent listing can support a Paragraph IV notice and litigation
Expected patent horizon	Public records have associated protection with the early 2030s, subject to applicable term calculations
Manufacturing protection	Likely dependent on process controls, specifications, and supply arrangements rather than a broad composition monopoly

Patent expiration should be confirmed against the current FDA Orange Book and the patent’s official term-adjustment record. A listed patent does not guarantee an enforceable barrier through its nominal expiration date. Claims may be narrowed, invalidated, disclaimed, or bypassed by a competing formulation.

What formulations are protected by BLOXIVERZ patents?

The commercial protection is directed to the approved neostigmine injectable product and related composition or use claims, rather than to the broad concept of using neostigmine for reversal. A generic applicant can seek approval for a formulation that is pharmaceutically equivalent or pursue a different regulatory route if it does not rely on the protected approval elements.

Manufacturing barriers can still matter. Sterile injectable products require validated aseptic processing, container-closure integrity, stability data, particulate control, and reliable active-pharmaceutical-ingredient supply. These requirements raise entry costs but do not create the same durable protection as a strong composition-of-matter patent.

When does BLOXIVERZ lose exclusivity?

BLOXIVERZ already lost its principal FDA regulatory exclusivity. The commercially relevant remaining question is patent and supply-chain exclusivity.

A generic entrant may be able to enter before patent expiration if it:

1. Certifies that listed patents are invalid or not infringed under Paragraph IV;
2. Waits for patent expiration;
3. Relies on a non-infringing formulation or route; or
4. Obtains authorization after settlement or litigation resolution.

The likely practical loss of exclusivity is therefore a staged process. Hospital contracts may preserve some branded volume after generic approval, but prices typically decline as additional suppliers qualify and purchasing organizations shift volume to lower-cost alternatives.

Which companies are challenging BLOXIVERZ?

The generic competitive field for neostigmine includes large injectable manufacturers and specialty generic companies. Relevant competitors may include Hikma, Fresenius Kabi, Dr. Reddy’s Laboratories, Sagent Pharmaceuticals, Eugia, and other FDA-approved injectable suppliers, depending on the specific presentation and approval status.

A competitor’s presence in the neostigmine market does not establish that it has challenged BLOXIVERZ patents. A Paragraph IV challenge must be assessed through FDA Orange Book certifications, ANDA litigation records, and court dockets. Public commercial competition can also occur through products that do not directly challenge an Orange Book patent.

Paragraph IV risk

A Paragraph IV certification creates a potential 45-day window for the patent owner to file suit. A timely suit can trigger an FDA approval stay of up to 30 months, subject to statutory exceptions and court developments.[4]

For BLOXIVERZ, the commercial impact of a Paragraph IV filing would depend on:

• Whether the listed patent remains enforceable;
• Whether the patent claims cover the proposed generic formulation;
• Whether the patent owner files suit within the statutory period;
• Whether the challenger receives first-filer exclusivity;
• Whether the parties settle before trial; and
• Whether other approved suppliers enter during the dispute.

No regulatory exclusivity remains to provide a broad independent barrier. Patent litigation is therefore the central legal mechanism for delaying a directly substitutable product.

How does BLOXIVERZ compare with sugammadex?

Sugammadex is the most important branded clinical alternative. It selectively binds steroidal neuromuscular blockers, principally rocuronium and vecuronium, and can produce more predictable reversal at deeper levels of blockade. Neostigmine remains useful when the level of blockade is sufficiently recovered, when cost is a major formulary consideration, or when the paralytic regimen does not make sugammadex the preferred option.

Factor	BLOXIVERZ	Sugammadex
Pharmacology	Acetylcholinesterase inhibition	Selective encapsulation of steroidal neuromuscular blockers
Main use	Reversal of nondepolarizing blockade	Reversal of rocuronium- or vecuronium-induced blockade
Cost profile	Generally lower-cost active ingredient and product	Higher acquisition cost in many hospital settings
Monitoring need	Greater dependence on adequate spontaneous recovery	More effective for deeper blockade when appropriately dosed
Generic pressure	High	Increasing as patent and exclusivity barriers expire
Formulary role	Cost-efficient standard option	Premium or clinically differentiated option
Revenue risk	Price erosion and substitution	Generic entry and hospital budget pressure

The market is not a simple one-for-one substitution. Anesthesia protocols, neuromuscular monitoring, patient risk, procedure mix, and hospital economics determine product selection. Sugammadex can expand the overall reversal market while reducing the share available to neostigmine in selected cases.

What is the financial trajectory for BLOXIVERZ?

BLOXIVERZ has the financial profile of a mature niche injectable rather than a growth-stage pharmaceutical asset.

Historical trajectory

The product generated commercial revenue after its 2013 launch and was part of the hospital injectable portfolio associated with Avadel Pharmaceuticals. Avadel later transferred or sold rights to products in this portfolio, including BLOXIVERZ, as part of its shift toward a sleep-medicine-focused business model.[5]

Current public company reports generally do not provide a standalone BLOXIVERZ revenue line. Financial analysis therefore relies on portfolio-level disclosure, product ownership records, hospital injectable market conditions, and competitive-entry indicators.

Financial driver	Directional effect
Surgical procedure volume	Positive
Hospital formulary retention	Positive
Generic entry	Negative
Sugammadex adoption	Negative to mixed
Injectable shortages	Can be positive or negative
Contract repricing	Negative for branded margins
Manufacturing reliability	Positive when supply is constrained
Regulatory or patent challenge	Negative if it accelerates entry
GPO concentration	Negative for price realization

Revenue likely followed a typical specialty-injectable pattern: initial uptake after approval, portfolio expansion through hospital contracting, maturity after exclusivity expiry, and later pressure from generic competition and alternative reversal agents.

Margin profile

BLOXIVERZ can generate attractive gross margins when supplied without interruption and protected from direct generic substitution. That margin profile weakens rapidly after multiple suppliers qualify. Hospital injectable prices are also affected by annual contract renewals, GPO rebates, chargebacks, wholesaler deductions, and shortage-driven purchasing.

The product’s economics are more sensitive to net price and manufacturing utilization than to consumer marketing. Sales-force spending can be limited because the principal customers are institutional buyers and anesthesia departments.

What generic launch scenarios exist for BLOXIVERZ?

Three scenarios are commercially relevant.

Scenario 1: No immediate direct generic launch

The product retains demand because of limited supplier capacity, complex sterile manufacturing, or unresolved patent issues. Net pricing declines gradually through contracting rather than collapsing.

Scenario 2: Single generic entrant

The first entrant captures price-sensitive hospital volume. The branded product may retain accounts that value continuity of supply, established labeling, or contractual reliability. Net price typically falls, but the decline can be moderated if the market has only one credible supplier.

Scenario 3: Multiple generic entrants

Several approved suppliers compete for the same hospital contracts. This produces the greatest price pressure, increases substitution, and can reduce branded revenue to a residual or shortage-driven position.

The most probable long-term outcome for a mature injectable is a smaller branded share with episodic revenue support from supply disruptions affecting competitors.

What patent litigation and settlement issues affect BLOXIVERZ?

Patent litigation risk is concentrated in the Orange Book-listed patent associated with the product. A settlement could establish a licensed entry date before patent expiration, but settlement terms are not necessarily public in full and may include supply, manufacturing, or other commercial provisions.

The commercial value of any settlement depends on:

• The agreed generic entry date;
• Whether the challenger receives authorized-generic rights;
• The number of other potential entrants;
• Whether the patent survives validity review;
• Whether the settlement includes supply commitments; and
• Whether FDA approval is delayed by regulatory deficiencies unrelated to patents.

A patent settlement that permits early entry can reduce the value of the remaining patent term even when the patent remains technically valid.

How strong is the BLOXIVERZ patent estate?

The estate is moderate at best.

Its strengths are the presence of product-linked patent protection, the cost and complexity of sterile injectable development, and the importance of an approved hospital supply source. Its weaknesses are the age of neostigmine, expired regulatory exclusivity, the narrow number of commercially relevant claims, and the availability of alternative development strategies.

Strength factor	Assessment
Novel active ingredient	Weak
Regulatory exclusivity	Expired
Product-specific patent	Material but limited
Sterile manufacturing barrier	Moderate
Clinical differentiation	Moderate against neostigmine generics, weaker against sugammadex
Pricing power	Low to moderate
Long-term revenue protection	Limited

What is the competitive landscape for hospital neuromuscular-blockade reversal?

The market has three layers:

1. Branded or authorized neostigmine products;
2. Generic neostigmine injectables; and
3. Sugammadex products, including branded and generic versions as available.

Hospital buyers increasingly evaluate total acquisition cost, supply continuity, inventory risk, and anesthesia outcomes. A supplier with reliable sterile capacity can gain share even without a strong patent estate. Conversely, a patent-protected product can lose commercial momentum if it experiences shortages or unfavorable contract pricing.

Geographically, the United States is the most relevant market for BLOXIVERZ because the brand, Orange Book listing, 505(b)(2) approval, and related litigation mechanisms are U.S.-specific. International revenue should not be assumed to track U.S. performance. Product names, regulatory pathways, reimbursement, and supplier competition differ by country.

What is the revenue exposure to BLOXIVERZ?

BLOXIVERZ is unlikely to be a material driver of consolidated revenue for a diversified pharmaceutical company. It can be strategically important within a hospital-injectables portfolio because it adds recurring operating-room demand and can benefit from supply shortages affecting competitors.

The product’s revenue exposure is concentrated in:

• U.S. hospital injectable purchasing;
• Elective and emergency surgical volume;
• Anesthesia protocol selection;
• Generic supplier count;
• Patent challenge timing; and
• Manufacturing continuity.

Investor valuation should treat BLOXIVERZ as a mature, cash-generating product with downside from direct generic entry, not as a long-duration growth asset.

Key Takeaways

• BLOXIVERZ is a mature U.S. hospital injectable containing neostigmine methylsulfate.
• FDA regulatory exclusivity has expired.
• The principal remaining protection is product-linked patent protection, historically associated with U.S. Patent No. 8,563,033 and an early-2030s expiration horizon in public records.
• Generic entry, not loss of clinical utility, is the main revenue risk.
• Sugammadex is the leading clinical substitute, while generic neostigmine is the leading economic substitute.
• Standalone current revenue is not separately disclosed in public company reporting.
• Manufacturing reliability and hospital contracting are as important as patent rights.
• The likely financial trajectory is mature revenue, gradual price erosion, and possible episodic upside during competitor shortages.
• Biosimilar risk does not apply because BLOXIVERZ is a small-molecule injectable.
• A Paragraph IV challenge could accelerate entry, but its impact depends on patent litigation, settlement terms, and the number of qualified generic suppliers.

FAQs

Is BLOXIVERZ a generic drug?

No. BLOXIVERZ is a branded neostigmine methylsulfate injection approved through the 505(b)(2) pathway. Generic neostigmine products may compete with it.

Does BLOXIVERZ have new chemical entity exclusivity?

No. Neostigmine is an established active ingredient. BLOXIVERZ received approval-related regulatory exclusivity rather than five-year new chemical entity exclusivity.

Is BLOXIVERZ interchangeable with sugammadex?

No. The products have different mechanisms and clinical use parameters. Sugammadex is specifically used to reverse rocuronium- or vecuronium-induced blockade, while neostigmine is used when adequate spontaneous recovery has occurred.

Can a generic manufacturer launch BLOXIVERZ before patent expiration?

Potentially. A generic applicant may challenge a listed patent through Paragraph IV, design around the claims, enter under an agreed settlement, or wait for patent expiration. Approval and launch timing depend on FDA and litigation outcomes.

Why can BLOXIVERZ remain commercially relevant after patent expiry?

Operating-room demand continues, and hospitals may prefer a lower-cost reversal agent. Shortages, limited sterile-injectable capacity, and formulary contracts can preserve sales even after direct generic competition becomes available.

References

1. U.S. Food and Drug Administration. (2013). BLOXIVERZ (neostigmine methylsulfate) injection, prescribing information.
2. U.S. Food and Drug Administration. (2024). 505(b)(2) applications.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications and patent certifications.
5. Avadel Pharmaceuticals plc. (2018). Annual report and public disclosures regarding hospital injectable products and portfolio transactions.